AQST Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 19:23):
Our systems believe the stock currently is undervalued by 0.19% compare to its pairs and should correct upwards.

Stats
Dagens volum	1.09M
Gjennomsnittsvolum	2.02M
Markedsverdi	220.77M
EPS	$-0.170 ( Q1 \| 2024-05-07 )
Neste inntjeningsdato	( $-0.110 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.39 (Sector) 42.63 (Industry) 0
ATR14	$0.00500 (0.21%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX 0.71%

AKAN -1.69%

ALIM -0.63%

AMPH -4.03%

AMYT 0.00%

ANIP -1.26%

AQST -6.73%

ASRT 0.00%

ATNX 0.00%

AVDL -2.13%

AYTU -1.37%

BFRI -0.89%

BGXX 8.34%

CLVR 0.00%

COLL 0.65%

CPIX -1.31%

CRDL -1.98%

CRON -1.72%

CYTH -3.40%

DCPH 0.00%

DERM -3.74%

DRRX 1.55%

DVAX -0.67%

EGRX -2.68%

EMBC -2.16%

EMBCV -9.33%

EOLS 1.94%

ESPR 7.66%

EVOK -4.54%

FLGC -1.96%

FLXN 0.00%

GHSI -1.68%

HCM 2.75%

HROW 0.29%

HUGE -3.81%

IMCC -4.13%

INCR 2.49%

IRWD 0.61%

ITCI -2.63%

IXHL 0.34%

JUPW 11.76%

KALA -2.93%

KIN 0.11%

KMDA -1.20%

LNTH 0.06%

NBIX 1.31%

NEPT 0.00%

NLTX 1.45%

OGI 0.97%

OPTN 1.44%

ORGO -2.68%

PAHC 1.88%

PCRX 0.21%

PETQ 0.63%

PLXP 0.00%

PPD 0.00%

PROC -0.32%

PRPH -2.63%

PTPI -1.20%

RDHL 1.67%

RDUS 0.52%

REPH -0.48%

RGC -5.03%

RMTI -2.84%

SCTL 0.92%

SCYX -3.75%

SIGA -1.75%

SISI -14.23%

SNDL 0.00%

SNOA 3.47%

SSIC -2.87%

SUPN -1.51%

SXTC 0.93%

THTX 0.30%

TKNO -10.22%

TLGT -13.85%

TLRY 0.90%

TXMD 3.11%

TYHT -3.90%

UPC 3.75%

VTRS -0.56%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-06-20	Morris Timothy E	Buy	38 000	Stock Option (right to purchase)
2024-06-20	Taglietti Marco	Buy	38 000	Stock Option (Right to Purchase)
2024-06-20	Brown Gregory B	Buy	38 000	Stock Option (Right to Purchase)
2024-06-20	Krop Julie	Buy	38 000	Stock Option (Right to Purchase)
2024-06-20	Cochran John	Buy	38 000	Stock Option (Right to Purchase)

INSIDER POWER
87.07
Last 98 transactions
Buy: 5 885 486 \| Sell: 282 172

Korrelasjon (AI algo v.1.1b): Undervalued: 0.19% $2.42 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: -0.25 (neutral)

Kort: 0.13 (neutral)

Signal:(49.123) Neutral

Aquestive Therapeutics Korrelasjon

10 Mest positive korrelasjoner
OZEM	1
CCLDO	0.967
REBN	0.95
NATL	0.945
HUMA	0.938
VTYX	0.923
LIDR	0.914
CCLD	0.914
HUMAW	0.913
EUDA	0.911

10 Mest negative korrelasjoner
FTRE	-0.95
NAAS	-0.928
AERT	-0.89
PZZA	-0.889
LRHC	-0.873
GIGM	-0.873
IVP	-0.871
BLMN	-0.866
HOVR	-0.865
AAPD	-0.862

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Aquestive Therapeutics Korrelasjon - Valuta/Råvare

0.35
( neutral )

0.72
( moderate )

0.00
( neutral )

0.75
( moderate )

0.00
( neutral )

-0.76
( moderate negative )

Aquestive Therapeutics Økonomi

Annual	2023
Omsetning:	$50.58M
Bruttogevinst:	$29.97M (59.25 %)
EPS:	$-0.130

FY	2023
Omsetning:	$50.58M
Bruttogevinst:	$29.97M (59.25 %)
EPS:	$-0.130

FY	2022
Omsetning:	$47.68M
Bruttogevinst:	$28.29M (59.34 %)
EPS:	$-1.240

FY	2021
Omsetning:	$50.83M
Bruttogevinst:	$50.83M (100.00 %)
EPS:	$-2.10

Financial Reports:

No articles found.

Aquestive Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Aquestive Therapeutics

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.